Page 36 - Roche Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Patients, allied health professionals, academia, global health think-tank and corporate partners launch the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) to tackle heart disease in Asia SINGAPORE - Media OutReach - 26 June 2023 - Today, patient organizations, allied health professionals, academia, corporate partners and a global health think-tank came together to launch the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD...

New coalition formed to fight heart disease across Asia

The In Vitro Diagnostics Market demand is expected to grow at a 4.8% CAGR between 2023 and 2033. The market is expected to reach a value of US$ 129.9 billion by 2033, up from US$ 81.3 billion in 2023.The demand for improved IVD testing is being driven by advances in medical science and complex disorders. Furthermore...

SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.In a phase 3 randomized controlled trial, more than 60% of adults with obesity and type 2 diabetes lost at least 10% of their body weight at 72 weeks if they were

Denifanstat was well-tolerated and met primary endpoint in planned interim readout with 67% of treated patients achieving ≥30% reductions in liver fat at week 26 compared to 18% placebo (p<0.001)